Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold ...

A recent study from the University of Pennsylvania has shown that the injectable drug semaglutide can help people lose a ...

Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...

Contrave and Wegovy are both weight loss medications. Learn about their effectiveness, side effects, costs, and which ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® ...

An estimated 15 million Americans are currently taking semaglutide weight loss drugs, which are proven to impact alcohol ...